상세 보기
In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
- Hwang, Jin Ho;
- Hsu, Chi-Yuan
Citations
WEB OF SCIENCE
1Citations
SCOPUS
1초록
EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.
- 제목
- In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
- 저자
- Hwang, Jin Ho; Hsu, Chi-Yuan
- DOI
- 10.7326/J24-0020
- 발행일
- 2024-04
- 유형
- Article
- 권
- 177
- 호
- 4
- 페이지
- JC40 ~ JC40
- 언어
- ENG
- 출판사
- AMER COLL PHYSICIANS
- 발행국가
- 미국
- ISSN
- E 1539-3704
P 0003-4819